Related Experiment Video
Updated: Jun 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice
Abstract:
Thanks to their predictable pharmacokinetics and ease of use, low-molecular-weight heparins (LMWHs) have established uses in the prevention and treatment of thrombotic diseases and as a replacement for unfractionated heparin (UFH). Although LMWHs as a class have similar antithrombotic effects, they comprise a diverse group of agents with distinct biochemical and pharmacological profiles. In light of the ongoing pressure to contain pharmacy costs, the diversity among the LMWHs and their benefits over UFH are important considerations in clinical practice.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Therapeutic Index
Venous Thrombosis III: Interprofessional Care
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
